CN100389109C - 非核苷逆转录酶抑制剂 - Google Patents

非核苷逆转录酶抑制剂 Download PDF

Info

Publication number
CN100389109C
CN100389109C CNB2004800044061A CN200480004406A CN100389109C CN 100389109 C CN100389109 C CN 100389109C CN B2004800044061 A CNB2004800044061 A CN B2004800044061A CN 200480004406 A CN200480004406 A CN 200480004406A CN 100389109 C CN100389109 C CN 100389109C
Authority
CN
China
Prior art keywords
alkyl
alkoxy
phenyl
substituted
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004800044061A
Other languages
English (en)
Chinese (zh)
Other versions
CN1751028A (zh
Inventor
J·P·杜恩
J·H·霍格
T·米尔扎德甘
S·斯沃洛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1751028A publication Critical patent/CN1751028A/zh
Application granted granted Critical
Publication of CN100389109C publication Critical patent/CN100389109C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB2004800044061A 2003-02-18 2004-02-17 非核苷逆转录酶抑制剂 Expired - Fee Related CN100389109C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44797403P 2003-02-18 2003-02-18
US60/447,974 2003-02-18

Publications (2)

Publication Number Publication Date
CN1751028A CN1751028A (zh) 2006-03-22
CN100389109C true CN100389109C (zh) 2008-05-21

Family

ID=32908518

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800044061A Expired - Fee Related CN100389109C (zh) 2003-02-18 2004-02-17 非核苷逆转录酶抑制剂

Country Status (17)

Country Link
US (1) US7241794B2 (https=)
EP (1) EP1597235B1 (https=)
JP (1) JP4608480B2 (https=)
KR (1) KR100776093B1 (https=)
CN (1) CN100389109C (https=)
AR (1) AR043195A1 (https=)
AT (1) ATE370124T1 (https=)
BR (1) BRPI0407591A (https=)
CA (1) CA2515151C (https=)
CL (1) CL2004000270A1 (https=)
DE (1) DE602004008227T2 (https=)
ES (1) ES2291854T3 (https=)
MX (1) MXPA05008748A (https=)
PL (1) PL378556A1 (https=)
RU (1) RU2305680C2 (https=)
TW (1) TW200423930A (https=)
WO (1) WO2004074257A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4041153B2 (ja) * 2003-05-07 2008-01-30 ファイザー・プロダクツ・インク カンナビノイド受容体リガンドとその使用
US8022225B2 (en) 2004-08-04 2011-09-20 Taisho Pharmaceutical Co., Ltd Triazole derivative
UA87884C2 (uk) * 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
EP1988083B1 (en) 2006-02-03 2014-04-02 Taisho Pharmaceutical Co., Ltd. Triazole derivative
JP5218737B2 (ja) * 2006-02-06 2013-06-26 大正製薬株式会社 スフィンゴシン−１−リン酸結合阻害物質
CA2642308C (en) * 2006-02-14 2013-12-17 Ihara Chemical Industry Co., Ltd. Process for production of 5-alkoxy-4-hydroxymethylpyrazole compound
CL2007002105A1 (es) * 2006-07-21 2008-02-22 Hoffmann La Roche Compuestos derivados de 2-[3-(3-cianofenoxi)(fenoxi o fenilsulfanil)]-n-fenil acetamida, inhibidores de la transcriptasa inversa del vih; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar u
CA2658984C (en) 2006-08-16 2014-12-02 Joshua Kennedy-Smith Non-nucleoside reverse transcriptase inhibitors
BRPI0809617A2 (pt) 2007-03-29 2014-09-16 Hoffmann La Roche Inibidores não-nucleosídicos da transcriptase reversa
DK2177512T3 (da) 2007-08-01 2012-06-18 Taisho Pharmaceutical Co Ltd S1P1-bindingshæmmer
RU2495878C2 (ru) * 2007-12-21 2013-10-20 Ф.Хоффманн-Ля Рош Аг Гетероциклические антивирусные соединения
DE102008015033A1 (de) * 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
SI2924034T1 (sl) * 2010-03-30 2017-05-31 Merck Canada Inc. Farmacevtski sestavek, ki obsega nenukleozidni inhibitor reverzne transkriptaze
CN103097357B (zh) 2010-07-15 2015-01-28 大日本住友制药株式会社 吡唑化合物
EP2508511A1 (en) * 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
CN104797255A (zh) 2012-06-20 2015-07-22 范德比尔特大学 作为mglur5受体变构调节剂的取代的双环烷氧基吡唑类似物
WO2013192343A1 (en) 2012-06-20 2013-12-27 Vanderbilt University Substituted bicyclic alkoxy pyrazole analogs as allosteric modulators of mglur5 receptors
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
AU2013363398B2 (en) 2012-12-20 2017-06-01 Tempest Therapeutics, Inc. Triazolone compounds and uses thereof
US9776976B2 (en) 2013-09-06 2017-10-03 Inception 2, Inc. Triazolone compounds and uses thereof
WO2015153304A1 (en) 2014-04-01 2015-10-08 Merck Sharp & Dohme Corp. Prodrugs of hiv reverse transcriptase inhibitors
EP3194386A2 (en) 2014-09-17 2017-07-26 Ironwood Pharmaceuticals, Inc. Sgc stimulators
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
CA2978066A1 (en) * 2015-03-19 2016-09-22 E I Du Pont De Nemours And Company Fungicidal pyrazoles
EP3478665A1 (en) * 2016-06-29 2019-05-08 Esteve Pharmaceuticals, S.A. Pyrazole derivatives having activity against pain
CN110818636A (zh) * 2019-11-29 2020-02-21 河北科技大学 一种化合物或其盐及其应用和合成方法
CN115677585B (zh) * 2022-10-31 2024-03-19 上海群力化工有限公司 一种甲醛吡唑衍生物的合成工艺

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002004424A1 (en) * 2000-07-07 2002-01-17 Pfizer Limited Pyrazole derivatives
WO2002030907A1 (en) * 2000-10-10 2002-04-18 F. Hoffmann-La Roche Ag Pyrazole derivatives for the treatment of viral diseases
WO2002100853A1 (en) * 2001-06-04 2002-12-19 F. Hoffmann-La Roche Ag Pyrazole derivatives as hiv reverse transcriptase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2157368C2 (ru) 1994-09-26 2000-10-10 Сионоги Энд Ко., Лтд. Производные имидазола и фармацевтическая композиция на их основе
DE19734664A1 (de) * 1997-08-11 1999-02-18 Bayer Ag (Hetero)Aryloxypyrazole
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
GB0028484D0 (en) 2000-11-22 2001-01-10 Hoffmann La Roche Imidazolone derivatives for the treatment of viral diseases
RS51166B (sr) * 2001-04-10 2010-10-31 Pfizer Inc. Derivati pirazola za tretiranje hiv

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002004424A1 (en) * 2000-07-07 2002-01-17 Pfizer Limited Pyrazole derivatives
WO2002030907A1 (en) * 2000-10-10 2002-04-18 F. Hoffmann-La Roche Ag Pyrazole derivatives for the treatment of viral diseases
WO2002100853A1 (en) * 2001-06-04 2002-12-19 F. Hoffmann-La Roche Ag Pyrazole derivatives as hiv reverse transcriptase inhibitors

Also Published As

Publication number Publication date
KR20050105471A (ko) 2005-11-04
US7241794B2 (en) 2007-07-10
AU2004213134A1 (en) 2004-09-02
RU2005128832A (ru) 2006-04-27
AR043195A1 (es) 2005-07-20
CN1751028A (zh) 2006-03-22
KR100776093B1 (ko) 2007-11-15
DE602004008227D1 (de) 2007-09-27
DE602004008227T2 (de) 2008-05-15
CA2515151C (en) 2010-11-30
BRPI0407591A (pt) 2006-02-14
ATE370124T1 (de) 2007-09-15
WO2004074257A1 (en) 2004-09-02
MXPA05008748A (es) 2005-09-20
TW200423930A (en) 2004-11-16
EP1597235A1 (en) 2005-11-23
EP1597235B1 (en) 2007-08-15
RU2305680C2 (ru) 2007-09-10
ES2291854T3 (es) 2008-03-01
CA2515151A1 (en) 2004-09-02
CL2004000270A1 (es) 2005-02-04
PL378556A1 (pl) 2006-05-02
JP2006515339A (ja) 2006-05-25
JP4608480B2 (ja) 2011-01-12
US20040192666A1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
CN100389109C (zh) 非核苷逆转录酶抑制剂
TWI235752B (en) Inhibitors of c-JUN N-terminal kinases (JNK) and other protein kinases
US11691978B2 (en) Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors
CA2505945A1 (en) Pyrazole derivatives useful as cox-i inhibitors
US7951956B2 (en) Benzoimidazole compound capable of inhibiting prostaglandin D synthetase
CN101360717B (zh) 包含嘧啶环的化合物
EP1673355A1 (en) Substituted triazole derivatives as oxytocin antagonists
EP1551828A1 (en) Pyrazole derivatives
EP2599775A1 (en) Ethinyl-pyrazole derivative
MX2010008414A (es) Heterociclos novedosos.
US20050054707A1 (en) Pyrazole derivatives
AU2004213134B2 (en) Non-nucleoside reverse transcriptase inhibitors
US20050004129A1 (en) Pyrazole derivatives
EP1546132A1 (en) Pyrazole derivatives as reverse transcriptase inhibitors
ES2305563T3 (es) Derivados de pirazol y su uso como agentes terapeuticos para enfermedades mediadas por el vih.
US7230025B2 (en) Pyrazole derivatives
WO2025209481A1 (zh) 吡唑并[3,4-d]哒嗪酮类化合物、其制备方法、药物组合物及其应用
TW200523254A (en) Large conductance calcium-activated k channel opener

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080521

Termination date: 20120217